Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
- Autori: Provenzani, A; Santeusanio, A; Mathis, E; Notarbartolo Di Villarosa, M; Labbozzetta, M; Poma, P; Provenzani, A; Polidori, C; Vizzini, G; Polidori, P; D'Alessandro, N
- Anno di pubblicazione: 2013
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: ABCB1; Calcineurin inhibitors; CYP3A4; CYP3A5; Kidney transplant; Liver transplant; Pharmacogenetics; Single nucleotide polymorphisms; Tacrolimus;
- OA Link: http://hdl.handle.net/10447/87745
Abstract
The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolimus; also, unlike phenotypic tests, the genotype is a stable characteristic that needs to be determined only once for any given gene. However, prospective clinical studies must show that genotype determination before transplantation allows for better use of a given drug and improves the safety and cli...